Thalassemia: An overview of 50 years of clinical research

Hematology/Oncology Clinics of North America

Volumn 24, Issue 6, 2010, Pages 1005-1020

  Sankaran, Vijay G ^a,b,c,d   Nathan, David G ^a,b,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Erythrocyte; Hemoglobin; Thalassemia; Transfusion

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; DEFEROXAMINE; HEMOGLOBIN;

BETA THALASSEMIA; BLOOD TRANSFUSION; CLINICAL RESEARCH; ERYTHROCYTE; ERYTHROPOIESIS; GENE THERAPY; HUMAN; IRON CHELATION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; STEM CELL TRANSPLANTATION; THALASSEMIA;

BIOMEDICAL RESEARCH; BLOOD TRANSFUSION; GENE THERAPY; GLOBINS; HUMANS; IRON CHELATING AGENTS; STEM CELL TRANSPLANTATION; THALASSEMIA;

EID: 78249272956     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.08.009     Document Type: Review

References (137)

1. Weatherall D.J., Clegg J.B. The thalassaemia syndromes 2001, Blackwell Science, Oxford; Malden (MA). 4th edition.
2. Olivieri N.F. The beta-thalassemias. N Engl J Med 1999, 341:99-109.
3. Rund D., Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005, 353:1135-1146.
4. Weatherall D.J. Thalassaemia: the long road from bedside to genome. Nat Rev Genet 2004, 5:625-631.
5. Ingram V.M., Stretton A.O. Genetic basis of the thalassaemia diseases. Nature 1959, 184:1903-1909.
6. Fessas P. Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia. Blood 1963, 21:21-32.
7. Fessas P., Loukopoulos D., Thorell B. Absorption spectra of inclusion bodies in beta-thalassemia. Blood 1965, 25:105-109.
8. Weatherall D.J., Clegg J.B., Naughton M.A. Globin synthesis in thalassaemia: an in vitro study. Nature 1965, 208:1061-1065.
9. Nathan D.G., Gunn R.B. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med 1966, 41:815-830.
10. Heywood J.D., Karon M., Weissman S. Amino acids: incorporation into alpha- and beta-chains of hemoglobin by normal and thalassemic reticulocytes. Science 1964, 146:530-531.
11. Marks P.A., Burka E.R. Hemoglobins A and F: formation in thalassemia and other hemolytic anemias. Science 1964, 144:552-553.
12. Gabuzda T.G., Nathan D.G., Gardner F.H., et al. Hemoglobin F and beta thalassemia. Science 1967, 157:1079.
13. Clegg J.B., Weatherall D.J. Haemoglobin synthesis in alpha-thalassaemia (haemoglobin H disease). Nature 1967, 215:1241-1243.
14. Clegg J.B., Weatherall D.J., Na-Nakorn S., et al. Haemoglobin synthesis in beta-thalassaemia. Nature 1968, 220:664-668.
15. Nienhuis A.W., Anderson W.F. Isolation and translation of hemoglobin messenger RNA from thalassemia, sickle cell anemia, and normal human reticulocytes. J Clin Invest 1971, 50:2458-2460.
16. Benz E.J., Forget B.G. Defect in messenger RNA for human hemoglobin synthesis in beta thalassemia. J Clin Invest 1971, 50:2755-2760.
17. Nathan D.G., Lodish H.F., Kan Y.W., et al. Beta thalassemia and translation of globin messenger RNA. Proc Natl Acad Sci U S A 1971, 68:2514-2518.
18. Bank A., Marks P.A. Hemoglobin synthesis in thalassemia. Semin Hematol 1971, 4:97-115.
19. Housman D., Forget B.G., Skoultchi A., et al. Quantitative deficiency of chain-specific globin messenger ribonucleic acids in the thalassemia syndromes. Proc Natl Acad Sci U S A 1973, 70:1809-1813.
20. Kacian D.L., Gambino R., Dow L.W., et al. Decreased globin messenger RNA in thalassemia detected by molecular hybridization. Proc Natl Acad Sci U S A 1973, 70:1886-1890.
21. Ottolenghi S., Lanyon W.G., Paul J., et al. The severe form of alpha thalassaemia is caused by a haemoglobin gene deletion. Nature 1974, 251:389-392.
22. Taylor J.M., Dozy A., Kan Y.W., et al. Genetic lesion in homozygous alpha thalassaemia (hydrops fetalis). Nature 1974, 251:392-393.
23. Orkin S.H., Old J., Lazarus H., et al. The molecular basis of alpha-thalassemias: frequent occurrence of dysfunctional alpha loci among non-Asians with Hb H disease. Cell 1979, 17:33-42.
24. Embury S.H., Lebo R.V., Dozy A.M., et al. Organization of the alpha-globin genes in the Chinese alpha-thalassemia syndromes. J Clin Invest 1979, 63:1307-1310.
25. Orkin S.H., Old J.M., Weatherall D.J., et al. Partial deletion of beta-globin gene DNA in certain patients with beta 0-thalassemia. Proc Natl Acad Sci U S A 1979, 76:2400-2404.
26. Kan Y.W., Dozy A.M. Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. Proc Natl Acad Sci U S A 1978, 75:5631-5635.
27. Antonarakis S.E., Boehm C.D., Giardina P.J., et al. Nonrandom association of polymorphic restriction sites in the beta-globin gene cluster. Proc Natl Acad Sci U S A 1982, 79:137-141.
28. Orkin S.H., Kazazian H.H., Antonarakis S.E., et al. Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. Nature 1982, 296:627-631.
29. De Gobbi M., Viprakasit V., Hughes J.R., et al. A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter. Science 2006, 312:1215-1217.
30. Kan Y.W., Golbus M.S., Trecartin R. Prenatal diagnosis of homozygous beta-thalassaemia. Lancet 1975, 2:790-791.
31. Kan Y.W., Golbus M.S., Klein P., et al. Successful application of prenatal diagnosis in a pregnancy at risk for homozygous beta-thalassemia. N Engl J Med 1975, 292:1096-1099.
32. Chang H., Hobbins J.C., Cividalli G., et al. In utero diagnosis of: hemoglobinopathies. Hemoglobin synthesis in fetal red cells. N Engl J Med 1974, 290:1067-1068.
33. Aleporou-Marinou V., Sakarelou-Papapetrou N., Antsaklis A., et al. Prenatal diagnosis of thalassemia major in Greece: evaluation of the first large series of attempts. Ann N Y Acad Sci 1980, 344:181-188.
34. Cao A., Rosatelli C., Pirastu M., et al. Thalassemias in Sardinia: molecular pathology, phenotype-genotype correlation, and prevention. Am J Pediatr Hematol Oncol 1991, 13:179-188.
35. Orkin S.H., Alter B.P., Altay C., et al. Application of endonuclease mapping to the analysis and prenatal diagnosis of thalassemias caused by globin-gene deletion. N Engl J Med 1978, 299:166-172.
36. Boehm C.D., Antonarakis S.E., Phillips J.A., et al. Prenatal diagnosis using DNA polymorphisms. Report on 95 pregnancies at risk for sickle-cell disease or beta-thalassemia. N Engl J Med 1983, 308:1054-1058.
37. Old J.M., Ward R.H., Petrou M., et al. First-trimester fetal diagnosis for haemoglobinopathies: three cases. Lancet 1982, 2:1413-1416.
38. Colah R., Surve R., Wadia M., et al. Carrier screening for beta-thalassemia during pregnancy in India: a 7-year evaluation. Genet Test 2008, 12:181-185.
39. Wolman I.J. Transfusion therapy in Cooley's anemia: growth and health as related to long-range hemoglobin levels. A progress report. Ann N Y Acad Sci 1964, 119:736-747.
40. Piomelli S., Danoff S.J., Becker M.H., et al. Prevention of bone malformations and cardiomegaly in Cooley's anemia by early hypertransfusion regimen. Ann N Y Acad Sci 1969, 165:427-436.
41. Propper R.D., Button L.N., Nathan D.G. New approaches to the transfusion management of thalassemia. Blood 1980, 55:55-60.
42. Nathan D.G. Thalassemia: the continued challenge. Ann N Y Acad Sci 2005, 1054:1-10.
43. Rebulla P. Blood transfusion in beta thalassaemia major. Transfus Med 1995, 5:247-258.
44. Sonakul D., Thakerngpol K., Pacharee P. Cardiac pathology in 76 thalassemic patients. Birth Defects Orig Artic Ser 1988, 23:177-191.
45. Link G., Pinson A., Hershko C. Heart cells in culture: a model of myocardial iron overload and chelation. J Lab Clin Med 1985, 106:147-153.
46. Kirk P., Roughton M., Porter J.B., et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009, 120:1961-1968.
47. Brittenham G.M., Farrell D.E., Harris J.W., et al. Magnetic-susceptibility measurement of human iron stores. N Engl J Med 1982, 307:1671-1675.
48. St Pierre T.G., Clark P.R., Chua-anusorn W., et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood 2005, 105:855-861.
49. Goldberg H.I., Cann C.E., Moss A.A., et al. Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. Invest Radiol 1982, 17:375-380.
50. Propper R.D., Cooper B., Rufo R.R., et al. Continuous subcutaneous administration of deferoxamine in patients with iron overload. N Engl J Med 1977, 297:418-423.
51. Propper R.D., Shurin S.B., Nathan D.G. Reassessment of the use of desferrioxamine B in iron overload. N Engl J Med 1976, 294:1421-1423.
52. Pippard M.J., Callender S.T., Weatherall D.J. Chelation regimens with desferrioxamine. Lancet 1977, 1:1101.
53. Olivieri N.F., Nathan D.G., MacMillan J.H., et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994, 331:574-578.
54. Brittenham G.M., Griffith P.M., Nienhuis A.W., et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994, 331:567-573.
55. Borgna-Pignatti C., Rugolotto S., De Stefano P., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
56. Cunningham M.J., Nathan D.G. New developments in iron chelators. Curr Opin Hematol 2005, 12:129-134.
57. Cohen A.R., Galanello R., Piga A., et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003, 102:1583-1587.
58. Hoffbrand A.V., AL-Refaie F., Davis B., et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998, 91:295-300.
59. Giardina P.J., Grady R.W. Chelation therapy in beta-thalassemia: an optimistic update. Semin Hematol 2001, 38:360-366.
60. Nisbet-Brown E., Olivieri N.F., Giardina P.J., et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003, 361:1597-1602.
61. Cappellini M.D., Pattoneri P. Oral iron chelators. Annu Rev Med 2009, 60:25-38.
62. Porter J., Galanello R., Saglio G., et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008, 80:168-176.
63. Vichinsky E., Onyekwere O., Porter J., et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007, 136:501-508.
64. Chirnomas D., Smith A., Braunstein J., et al. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006, 107:3436-3441.
65. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 2003, 102:783-788.
66. Nemeth E., Ganz T. The role of hepcidin in iron metabolism. Acta Haematol 2009, 122:78-86.
67. Tanno T., Bhanu N.V., Oneal P.A., et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat Med 2007, 13:1096-1101.
68. Gardenghi S., Marongiu M.F., Ramos P., et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. Blood 2007, 109:5027-5035.
69. Li H., Rybicki A.C., Suzuka S.M., et al. Transferrin therapy ameliorates disease in beta-thalassemic mice. Nat Med 2010, 16:177-182.
70. Weatherall D.J. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet 2001, 2:245-255.
71. Premawardhena A., Fisher C.A., Olivieri N.F., et al. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet 2005, 366:1467-1470.
72. Galanello R., Sanna S., Perseu L., et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. Blood 2009, 114:3935-3937.
73. Nuinoon M., Makarasara W., Mushiroda T., et al. A genome-wide association identified the common genetic variants influence disease severity in beta(0)-thalassemia/hemoglobin E. Hum Genet 2010, 127:303-314.
74. Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood 2006, 107:435-443.
75. Stamatoyannopoulos G. Control of globin gene expression during development and erythroid differentiation. Exp Hematol 2005, 33:259-271.
76. Fritsch E.F., Lawn R.M., Maniatis T. Molecular cloning and characterization of the human beta-like globin gene cluster. Cell 1980, 19:959-972.
77. DeSimone J., Heller P., Hall L., et al. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci U S A 1982, 79:4428-4431.
78. Ley T.J., Anagnou N.P., Young N.S., et al. 5-Azacytidine for beta thalassaemia?. Lancet 1983, 1:467.
79. Ley T.J., DeSimone J., Anagnou N.P., et al. 5-Azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N Engl J Med 1982, 307:1469-1475.
80. Ley T.J., DeSimone J., Noguchi C.T., et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 1983, 62:370-380.
81. Benz E.J. Clinical management of gene expression. N Engl J Med 1982, 307:1515-1516.
82. Nathan D.G. Regulation of fetal hemoglobin synthesis by cell cycle specific drugs. Prog Clin Biol Res 1985, 191:475-500.
83. Letvin N.L., Linch D.C., Beardsley G.P., et al. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. J Clin Invest 1985, 75:1999-2005.
84. Letvin N.L., Linch D.C., Beardsley G.P., et al. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984, 310:869-873.
85. Papayannopoulou T., Torrealba de Ron A., Veith R., et al. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. Science 1984, 224:617-619.
86. Platt O.S., Orkin S.H., Dover G., et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. J Clin Invest 1984, 74:652-656.
87. Platt O.S. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med 2008, 358:1362-1369.
88. Charache S., Terrin M.L., Moore R.D., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995, 332:1317-1322.
89. Steinberg M.H., Barton F., Castro O., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA 2003, 289:1645-1651.
90. Yavarian M., Karimi M., Bakker E., et al. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. Haematologica 2004, 89:1172-1178.
91. Alebouyeh M., Moussavi F., Haddad-Deylami H., et al. Hydroxyurea in the treatment of major beta-thalassemia and importance of genetic screening. Ann Hematol 2004, 83:430-433.
92. Perrine S.P., Greene M.F., Faller D.V. Delay in the fetal globin switch in infants of diabetic mothers. N Engl J Med 1985, 312:334-338.
93. Bard H., Prosmanne J. Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. Pediatrics 1985, 75:1143-1147.
94. Perrine S.P., Rudolph A., Faller D.V., et al. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. Proc Natl Acad Sci U S A 1988, 85:8540-8542.
95. Perrine S.P., Ginder G.D., Faller D.V., et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993, 328:81-86.
96. Perrine S.P., Olivieri N.F., Faller D.V., et al. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. Am J Pediatr Hematol Oncol 1994, 16:67-71.
97. Sher G.D., Ginder G.D., Little J., et al. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. N Engl J Med 1995, 332:1606-1610.
98. Dover G.J., Brusilow S., Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994, 84:339-343.
99. Dover G.J., Brusilow S., Samid D. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. N Engl J Med 1992, 327:569-570.
100. Fathallah H., Weinberg R.S., Galperin Y., et al. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 2007, 110:3391-3397.
101. Cao H., Stamatoyannopoulos G., Jung M. Induction of human gamma globin gene expression by histone deacetylase inhibitors. Blood 2004, 103:701-709.
102. Quek L., Thein S.L. Molecular therapies in beta-thalassaemia. Br J Haematol 2007, 136:353-365.
103. Cantor A.B., Orkin S.H. Transcriptional regulation of erythropoiesis: an affair involving multiple partners. Oncogene 2002, 21:3368-3376.
104. McCarthy M.I., Abecasis G.R., Cardon L.R., et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 2008, 9:356-369.
105. Uda M., Galanello R., Sanna S., et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A 2008, 105:1620-1625.
106. Menzel S., Garner C., Gut I., et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007, 39:1197-1199.
107. Lettre G., Sankaran V.G., Bezerra M.A., et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A 2008, 105:11869-11874.
108. Sankaran V.G., Menne T.F., Xu J., et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008, 322:1839-1842.
109. Sankaran V.G., Xu J., Ragoczy T., et al. Developmental and species-divergent globin switching are driven by BCL11A. Nature 2009, 460:1093-1097.
110. Kan Y.W., Nathan D.G. Mild thalassemia: the result of interactions of alpha and beta thalassemia genes. J Clin Invest 1970, 49:635-642.
111. Higgs D.R. Gene regulation in hematopoiesis: new lessons from thalassemia. Hematology Am Soc Hematol Educ Program 2004, 1-13.
112. Bordignon C. Stem-cell therapies for blood diseases. Nature 2006, 441:1100-1102.
113. Gaziev J., Sodani P., Polchi P., et al. Bone marrow transplantation in adults with thalassemia: treatment and long-term follow-up. Ann N Y Acad Sci 2005, 1054:196-205.
114. Chandy M. Stem cell transplantation in India. Bone Marrow Transplant 2008, 42(Suppl 1):S81-S84.
115. Hsieh M.M., Kang E.M., Fitzhugh C.D., et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009, 361:2309-2317.
116. Locatelli F. Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. Hematology Am Soc Hematol Educ Program 2006, 398-401.
117. Paciaroni K., Gallucci C., De Angelis G., et al. Sustained and full fetal hemoglobin production after failure of bone marrow transplant in a patient homozygous for beta 0-thalassemia: a clinical remission despite genetic disease and transplant rejection. Am J Hematol 2009, 84:372-373.
118. Ferster A., Corazza F., Vertongen F., et al. Transplanted sickle-cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity. Br J Haematol 1995, 90:804-808.
119. Williams D.A., Lemischka I.R., Nathan D.G., et al. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse. Nature 1984, 310:476-480.
120. Woo S.L. Policy statement of the American Society of Gene Therapy on reporting of patient adverse events in gene therapy trials. Mol Ther 2000, 1:7-8.
121. Fischer A., Abina S.H., Thrasher A., et al. LMO2 and gene therapy for severe combined immunodeficiency. N Engl J Med 2004, 350:2526-2527. [author reply: 2526-7].
122. Cavazzana-Calvo M., Payen E., Negre O., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010, 467(7313):318-322.
123. Imren S., Payen E., Westerman K.A., et al. Permanent and panerythroid correction of murine beta thalassemia by multiple lentiviral integration in hematopoietic stem cells. Proc Natl Acad Sci U S A 2002, 99:14380-14385.
124. Rivella S., May C., Chadburn A., et al. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003, 101:2932-2939.
125. May C., Rivella S., Callegari J., et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000, 406:82-86.
126. May C., Rivella S., Chadburn A., et al. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002, 99:1902-1908.
127. Lisowski L., Sadelain M. Current status of globin gene therapy for the treatment of beta-thalassaemia. Br J Haematol 2008, 141:335-345.
128. Bank A., Dorazio R., Leboulch P. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. Ann N Y Acad Sci 2005, 1054:308-316.
129. Porteus M.H., Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science 2003, 300:763.
130. Porteus M.H., Carroll D. Gene targeting using zinc finger nucleases. Nat Biotechnol 2005, 23:967-973.
131. Urnov F.D., Miller J.C., Lee Y.L., et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005, 435:646-651.
132. Belmonte J.C., Ellis J., Hochedlinger K., et al. Induced pluripotent stem cells and reprogramming: seeing the science through the hype. Nat Rev Genet 2009, 10:878-883.
133. Hanna J., Wernig M., Markoulaki S., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318:1920-1923.
134. Daley G.Q. Stem cells: roadmap to the clinic. J Clin Invest 2010, 120:8-10.
135. Nathan D.G. The several Cs of translational clinical research. J Clin Invest 2005, 115:795-797.
136. Goldstein J.L., Brown M.S. The clinical investigator: bewitched, bothered, and bewildered-but still beloved. J Clin Invest 1997, 99:2803-2812.
137. Weatherall D., Akinyanju O., Fucharoen S., et al. Inherited disorders of hemoglobin. Disease control priorities in developing countries 2006, Oxford University Press, New York, p. 663-80. 2nd edition.